[
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson (JNJ): AAA Balance Sheet… An Unjustified Casualty of Pharma Tariffs",
    "summary": "We recently published a list of Jim Cramer Questions Market Logic and Dissects These 7 Key Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer unpacked the deepening uncertainty […]",
    "url": "https://finnhub.io/api/news?id=0830c6181998238c6377bd6469e37f6736543cfd376c057f9d9fed5debb4468a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744394342,
      "headline": "Jim Cramer on Johnson & Johnson (JNJ): AAA Balance Sheet… An Unjustified Casualty of Pharma Tariffs",
      "id": 133880636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Questions Market Logic and Dissects These 7 Key Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer unpacked the deepening uncertainty […]",
      "url": "https://finnhub.io/api/news?id=0830c6181998238c6377bd6469e37f6736543cfd376c057f9d9fed5debb4468a"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings",
    "summary": "JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.",
    "url": "https://finnhub.io/api/news?id=b0177ad83e4a7e1f59ab2b380180ef7567bcb0f77ab3e099647c0425e4944f1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744385520,
      "headline": "Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings",
      "id": 133880637,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.",
      "url": "https://finnhub.io/api/news?id=b0177ad83e4a7e1f59ab2b380180ef7567bcb0f77ab3e099647c0425e4944f1e"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744377180,
      "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "id": 134146899,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Goldman Sachs, TSMC, ASML, Netflix, LVMH and Sainsbury's",
    "summary": "Earnings preview of key companies reporting next week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=e980850a83a063593803d9a3d517b7f6bfb768974177f200353173e137a28ce5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744377071,
      "headline": "Stocks to watch next week: Goldman Sachs, TSMC, ASML, Netflix, LVMH and Sainsbury's",
      "id": 133880468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting next week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=e980850a83a063593803d9a3d517b7f6bfb768974177f200353173e137a28ce5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Fairly Valued, But Recession-Resilient",
    "summary": "Johnson & Johnson: Fairly Valued, But Recession-Resilient",
    "url": "https://finnhub.io/api/news?id=7848c0eb3083a1aaf46c8635281f7b904bb1149f57d2a4e8f9a9649b34de13af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744375602,
      "headline": "Johnson & Johnson: Fairly Valued, But Recession-Resilient",
      "id": 133879772,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7848c0eb3083a1aaf46c8635281f7b904bb1149f57d2a4e8f9a9649b34de13af"
    }
  },
  {
    "ts": null,
    "headline": "IGD: Capital Erosion And Shrinking Dividend Payouts",
    "summary": "IGD: Capital Erosion And Shrinking Dividend Payouts",
    "url": "https://finnhub.io/api/news?id=d33be69e95088ba151b58ecb5fd917a4d6e1acc08d3342f4e47664da20f2f5b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744375500,
      "headline": "IGD: Capital Erosion And Shrinking Dividend Payouts",
      "id": 133879773,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d33be69e95088ba151b58ecb5fd917a4d6e1acc08d3342f4e47664da20f2f5b4"
    }
  },
  {
    "ts": null,
    "headline": "J&J reports analysis from Phase III trial of plaque psoriasis treatment",
    "summary": "The safety profile of icotrokinra was demonstrated to be 'favourable', according to the company.",
    "url": "https://finnhub.io/api/news?id=aa5ed3bb3f4de04631babaf63cfe6cc4d7f806ff2fcd6306ae19ea053a4370ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744371715,
      "headline": "J&J reports analysis from Phase III trial of plaque psoriasis treatment",
      "id": 133880639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The safety profile of icotrokinra was demonstrated to be 'favourable', according to the company.",
      "url": "https://finnhub.io/api/news?id=aa5ed3bb3f4de04631babaf63cfe6cc4d7f806ff2fcd6306ae19ea053a4370ac"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy Right Now",
    "summary": "Microsoft (NASDAQ: MSFT) and Johnson & Johnson (NYSE: JNJ) are leading companies in their respective industries.  Microsoft's market cap is $2.6 trillion, so some detractors feel it has little room to grow.  Meanwhile, Johnson & Johnson is still dealing with thousands of talc-related lawsuits, and recently hit another road bump in that department.",
    "url": "https://finnhub.io/api/news?id=45696fb492cb310fb5f647127f7acb2625a6817a3809e64a1a6daae436662047",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744359900,
      "headline": "2 Top Dividend Stocks to Buy Right Now",
      "id": 133880456,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Microsoft (NASDAQ: MSFT) and Johnson & Johnson (NYSE: JNJ) are leading companies in their respective industries.  Microsoft's market cap is $2.6 trillion, so some detractors feel it has little room to grow.  Meanwhile, Johnson & Johnson is still dealing with thousands of talc-related lawsuits, and recently hit another road bump in that department.",
      "url": "https://finnhub.io/api/news?id=45696fb492cb310fb5f647127f7acb2625a6817a3809e64a1a6daae436662047"
    }
  },
  {
    "ts": null,
    "headline": "Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)",
    "summary": "Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)",
    "url": "https://finnhub.io/api/news?id=3c446a771dc69e5b1078f9eaf4ab2d8673f412338e41053698e9a5c5f325389e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744345257,
      "headline": "Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)",
      "id": 133877063,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3c446a771dc69e5b1078f9eaf4ab2d8673f412338e41053698e9a5c5f325389e"
    }
  }
]